Inhibitors of spinster homolog 2 (spns2) for use in therapy

A compound according to Formula I:

• wherein
• X is a C6-C10-aryl or 5- to 10-membered heteroaryl (wherein 1-4 heteroaryl members are independently selected from N, O, and S);
• R1 and R2 are independently selected from the group consisting of H, C1-C6-alkyl, C1-C6-alkoxy, C3-C8-cycloalkyl, C1-C6-haloalkyl, CN, and halo;
• R3 is H or —C(NH)NH2;
• W is a bond, CH2, O, NH, —O—N═C(R)—, or —N(R)—C(O)— (wherein R is H or C1-C6-alkyl);
• V is selected from the group consisting of H, C1-C14-alkyl, C2-C12-alkenyl, (C6-C10)aryl, —C1-C10-alkyl-(C6-C10)aryl, —C2-C12-alkenyl-(C6-C10)aryl, —C1-C10-alkyl-(C3-C5)cycloalkyl, -(3- to 14-membered heterocycloalkyl) (wherein 1-4 heterocycloalkyl members are independently selected from N, O, and S), —(C1-C10)alkyl-(3- to 14-membered heterocycloalkyl) (wherein 1-4 heterocycloalkyl members are independently selected from N, O, and S);
• m is 0 or 1;
• n is 1, 2, 3, or 4;
• each alkyl, alkoxy, alkenyl, alkynyl, aryl, cycloalkyl, heterocycloalkyl, and heteroaryl is optionally substituted with 1-5 substituents independently selected from the group consisting of hydroxy, halo, —NR′2 [wherein each R′ is independently selected from the group consisting of C1-C6-alkyl, C2-C6-alkenyl, C2-C6-alkynyl, C6-C10-aryl, 3- to 14-membered heterocycloalkyl and —(C1-C6-alkyl)-(3- to 14-membered heterocycloalkyl) (wherein 1-4 ring members are independently selected from N, O, and S), and 5- to 10-membered heteroaryl (wherein 1-4 heteroaryl members are independently selected from N, O, and S], —NHC(O)(OC1-C6-alkyl), —NO2, —CN, oxo, —C(O)OH, —C(O)O(C1-C6-alkyl), —C1-C6-alkyl(C1-C6-alkoxy), —C(O)NH2, C1-C6-alkyl, —C(O)C1-C6-alkyl, —OC1-C6-alkyl, —Si(C1-C6-alkyl)3, —S(O)0-2-(C1-C6-alkyl), C6-C10-aryl, —(C1-C6-alkyl)(C6-C10-aryl), 3- to 14-membered heterocycloalkyl, and —(C1-C6-alkyl)-(3- to 14-membered heterocycle) (wherein 1-4 heterocycle members are independently selected from N, O, and S), and —O(C6-C14-aryl),
• wherein each alkyl, alkenyl, aryl, and heterocycloalkyl is optionally substituted with one or more substituents selected from the group consisting of hydroxy, —OC1-C6-alkyl, halo, —NH2, —(C1-C6-alkyl)NH2, —C(O)OH, CN, and oxo,
• or a pharmaceutically acceptable salt thereof,
• and wherein the compound is not
• 3-(3-(4-octylphenyl)-1,2,4-oxadiazol-5-yl)pyrrolidine-1-carboximidamide,
• 3-(3-(4-octylphenyl)-1,2,4-oxadiazol-5-yl)azetidine-1-carboximidamide, or
• 3-(3-(4-decylphenyl)-1,2,4-oxadiazol-5-yl)azetidine-1-carboximidamide.